Navigation Links
NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
Date:4/1/2009

logical efficacy in-vivo in treating subcutaneous dermatophyte infections based on an established animal model. Importantly, these data combined with the past preclinical work that showed NVC-422 kills P. Acne, in the follicle, strongly suggest that NVC-422 may be a potent and well-tolerated treatment for acne and other numerous serious skin infections.

  • Hospital infections: In May 2008, NovaBay successfully completed a Phase I trial that showed NVC-422 was well tolerated in the bladder as a lavage solution for catheterized patients. In November 2008, the company commenced patient enrollment in a Phase II exploratory study of hospitalized patients who are catheterized and have bacteriuria. Data from this ongoing study, which is expected later this year, if positive, will provide support for future development plans for catheter-associated urinary tract infections, the most common hospital-acquired infection.

  • Respiratory infections: In May 2008, NovaBay completed its Phase IIa study of NVC-422 for nasal decolonization of Staphylococcus aureus, including MRSA (Methicillin Resistant Staphylococcus Aureus). In this study, two concentrations of a prototype nasal spray formulation of NVC-422 were tested to decolonize the lower nasal passages and were both found to be well tolerated. Based on a statistical analysis the higher dose treatment group provided consistent S. aureus reduction below the baseline score throughout the treatment period.

  • Intellectual property: NovaBay continues to solidify and expand its proprietary position in the Aganocide compounds and related antimicrobial technologies. NovaBay's key composition of matter patent for Aganocide compounds, including NVC-422, was issued by the U.S. Patent and Trademark Office
    '/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
2. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
3. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
4. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
5. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
6. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
9. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
10. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... MD (PRWEB) December 23, 2014 ... into law H.R. 83, the Omnibus and Continuing ... first time, made hydrocephalus a condition eligible to ... Programs (CDMRP) administered by the Department of Defense ... with its allies on Capitol Hill, is celebrating ...
(Date:12/24/2014)... December 24, 2014 The report expects ... 19.7% by 2019. It also provides a carefully analyzed ... and challenges for the market. , Full Copy of ... report, the global market for cell expansion will keep ... It expects this growth to be driven by rapid ...
(Date:12/24/2014)... December 23, 2014 PharmaBoardroom,s ... out today and available for free download , digs ... change and growth in the sector today. One ... successes has been in developing a homegrown pharmaceutical manufacturing base, ... production still remains some way off. A cursory comparison with ...
(Date:12/22/2014)... The Center for Professional Innovation ... training across the life sciences industry, has partnered with ... to provide the organization's members with discounted classroom courses, ... the more than 350 sessions across 80 course titles. ... when registering for a public course at ...
Breaking Biology Technology:Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... Inc. (Nasdaq: HGSI ) today announced that ... financial results for the year ended December 31, 2008. ... Thursday, February 26, 2009, after the capital markets close.(Logo: ... hosted by senior management and will be held on ...
... Feb. 19 Based on its recent analysis of ... Inc. with the 2009 North American Frost & Sullivan ... Award recognizes the company,s impressive progress in developing to ... guidance system that is set to redefine the standard ...
... -- Progen board; - finally ... Meeting; ... buyback; and - persists with ... meeting with refusal to align meeting datesShareholder Meeting scheduled for 27 ...
Cached Biology Technology:Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results 2Frost & Sullivan Names Naviscan a Leader in the Future of Molecular Breast Imaging 2Frost & Sullivan Names Naviscan a Leader in the Future of Molecular Breast Imaging 3Frost & Sullivan Names Naviscan a Leader in the Future of Molecular Breast Imaging 4Progen Concedes Shareholder Requisitioned Meeting 2Progen Concedes Shareholder Requisitioned Meeting 3Progen Concedes Shareholder Requisitioned Meeting 4Progen Concedes Shareholder Requisitioned Meeting 5
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... of the "Micro Market Monitor: North America Perimeter ... http://photos.prnewswire.com/prnh/20130307/600769 The ... at a CAGR of 3.6% from 2014 to 2019. ... this market, Canada is expected ...
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ... is accurate, flexible and robust – with the clinical ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... a gene called p63 accelerates aging in mice. Similar versions ... Therefore, the p63 gene is likely to play a fundamental ... p63 gene works, we devised a system for eliminating it ... that these p63 deficient mice were aging prematurely," says Alea ...
... a genetic study has followed a single humpback whale ... notions of the migratory patterns of these majestic marine ... Wildlife Conservation Society (WCS), the American Museum of Natural ... recent Royal Society's Biology Letters, a male humpback whale ...
... of the varicella (chicken pox) vaccine in 1995, hospitalizations ... dramatically, according to a study in the August 17 ... routine immunization of children aged 12 to 18 months ... United States, according to background information in the article. ...
Cached Biology News:Gene loss accelerates aging 2Genetics links whale to two different ocean basins 2Hospitalizations because of chicken pox down dramatically since implementation of vaccine 2Hospitalizations because of chicken pox down dramatically since implementation of vaccine 3
Mus musculus MARCKS-like protein, mRNA...
... from BRAND adds ergonomics and ease-of-use ... only electronic, motor-driven repeating pipette compatible ... BRAND PD-Tip syringe tips, Eppendorf Combi-Tips ... VWRbrand Combi-Syringes. Select virtually any pipetting ...
... can be used for efficient, mild and ... for ELISA or other assays for protein ... are bound with high efficiency to the ... will not elute during the assay due ...
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Biology Products: